Skip to Main Content
Our Commitment to Diversity
Schevon Salmon

Schevon Salmon is admitted to practice in the District of Columbia and Pennsylvania. He is not currently admitted in North Carolina.

Schevon Salmon is counsel and a member of the Health Care and FDA practice. His practice focuses on counseling companies through the development and manufacturing of pharmaceuticals, biologics, and medical devices at all stages of the product lifecycle. He advises clients on a variety of FDA regulatory and corporate transaction matters, including product development, advertising and promotion, medical communications, good manufacturing practices (drugs and medical devices), and negotiating quality and supply agreements.

Prior to joining the firm, Schevon was a director, corporate counsel at a global pharmaceutical company, where he focused on providing strategic and risked-based guidance to internal stakeholders on a variety of legal, regulatory, and compliance issues related to product development, manufacturing, and promotional activities. Through this role, he collaborated with senior leaders, subject matter experts, and cross-functional teams to develop and implement solutions and accomplish enterprise-wide business initiatives.

Before going in-house, Schevon worked at a boutique FDA law firm, where he represented clients before the FDA, US Department of Agriculture (USDA), Customs and Border Protection (CBP), and Environmental Protection Agency (EPA) on a wide range of issues related to regulatory classifications, marketing pathways, compliance, and enforcement actions.

  • Food and Drug Law Institute’s 2023 Rising Star Award
  • Food and Drug Law Institute
    • Annual Conference Planning Committee (2024-present)
    • Award Committee (2024-present)
    • Products Committee (2020-2022)
  • Drug and Device Uses of Digital Health Tools: Considerations for Advertising and Promotion, Food and Drug Law Institute: Advertising and Promotion for Medical Products Conference, 13 October 2024 
  • How-Tos for Developing a New Pro Bono Program, ACC NRC and Washington Council of Lawyers, 14 September 2021
  • FDA’s Framework for Drug-Use Software: Is This the Future, Food and Drug Law Institute: Advertising and Promotion for Medical Products Conference, 29 October 2020
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel